

Ontario Public Drug Programs

Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs

March 5, 2018

Ontario has been working with other provincial, territorial and federal drug programs in consultation with pharmaceutical manufacturers on a pan-Canadian initiative to reduce prices for selected generic products. The list of generic molecules has been available publicly since the announcement of the pan-Canadian initiative in January.

Effective April 1, 2018, the Drug Benefit Prices (DBP) of the following 59 generic molecules on the Ontario Drug Benefit (ODB) Formulary will be reduced:

- Alendronate
- Amiodarone
- Amlodipine
- Anastrozole
- Atenolol
- Atorvastatin
- Azithromycin
- Bicalutamide
- Bisoprolol
- Candesartan
- Candesartan/HCTZ
- Carvedilol
- Celecoxib
- Ciprofloxacin
- Citalopram
- Clonazepam
- Clopidogrel

- Domperidone
- Donepezil
- Dutasteride
- Escitalopram
- Ezetimibe
- Famciclovir
- Finasteride
- Fluoxetine
- Gabapentin
- Imatinib
- Irbesartan
- Irbesartan/HCTZ
- Lamotrigine
- Levetiracetam
- Metformin
- Montelukast
- Mycophenolate mofetil
- Olanzapine
- Olanzapine ODT
- Omeprazole
- Pantoprazole sodium
- Paroxetine
- Pramipexole
- Pravastatin
- Pregabalin
- Quetiapine
- Rabeprazole
- Ramipril
- Ranitidine
- Risedronate
- Risperidone
- Rosuvastatin
- Sertraline
- Simvastatin
- Solifenacin

- Telmisartan
- Telmisartan/HCTZ
- Topiramate
- Valacyclovir
- Valsartan
- Valsartan/HCTZ
- Venlafaxine

The Ministry has posted a new file with the details of the listing changes for download and review (Edition No. 43, Summary of Changes – April 1, 2018). It is accessible from the Ministry's website: http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx

In addition, the Formulary, Summaries of Changes and Bulletins, including a searchable electronic version of the Formulary (e-Formulary), are also accessible from the Ministry's website: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_iformulary.aspx. The e-Formulary will be updated on the effective date – April 1, 2018.

We appreciate your continued cooperation in making these benefit adjustments.